Cell Source, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Cell Source, Inc. (CLCS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.10 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2024-06-24.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-06-24
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.10, a 37.50% decline from fiscal 2021.
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $0.16, a 23.08% increase from fiscal 2020.
- Cell Source, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $0.13.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2022-12-31 | $0.10 10-K · filed 2024-06-24 |
| 2021-12-31 | $0.16 10-K · filed 2023-08-08 |
| 2020-12-31 | $0.13 10-K · filed 2022-04-15 |